Intellia Therapeutics downgraded by Morgan Stanley with a new price target

1/27/25 7:46:55 AM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Morgan Stanley downgraded Intellia Therapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $56.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NTLA

Date	Price Target	Rating	Analyst
4/21/2025	$21.00	Peer Perform → Outperform	Wolfe Research
3/5/2025	$30.00	Buy	H.C. Wainwright
2/28/2025	$45.00 → $13.00	Overweight → Neutral	Analyst
2/28/2025	$9.00	Neutral → Sell	Goldman
1/27/2025	$56.00 → $11.00	Overweight → Equal-Weight	Morgan Stanley
2/23/2024	$136.00 → $32.00	Buy → Neutral	Goldman
2/15/2024		Peer Perform	Wolfe Research
4/13/2023	$66.00	Buy	Canaccord Genuity